PharmiWeb

Star Therapeutics Presents Interim Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease, Demonstrating Substantial Bleed Reductions in All Patients, at ASH ...

VGA039 is a once monthly, subcutaneously self-administered therapy for the treatment of bleeding disorders, starting with von Willebrand disease (VWD)Multidose data demonstrate substantial reductions ...
PharmiWeb

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematol…

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit ...
PharmiWeb

AMEEREX Signs MOU to Acquire 45.6 million-Ounce Silver-Gold Project in Nevada, Expanding Its North American Precious-Metals Portfolio

ATLANTA, GA AND DOHA, QATAR / ACCESS Newswire / December 6, 2025 / Ameerex Corporation (OTC:HIRU) ("Ameerex" or the "Company"), a natural-resources group owned and managed by high-profile Qatari ...
PharmiWeb

Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and ...

New two- and three-year EPCORE® NHL-2 follow-up data evaluating epcoritamab in combination with standard of care regimens demonstrate remission in patients with DLBCL and FLLatest EPCORE DLBCL-3 trial ...
PharmiWeb

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global ...

Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in ...
PharmiWeb

Genetix Participates in the American Society of Hematology’s (ASH) Exclusive Press Program & Shares Recent Patient Experience Data from U.S. Commercial Gene Therapy ...

Data presented was selected for ASH’s exclusive program to highlight the most impactful research submitted for this year’s meetingReal-world data reinforces the value of durable, one-time gene ...
PharmiWeb

Ayrmid Reports Promising New Real-World Data on Motixafortide for Stem Cell Mobilization in Sickle Cell Disease

Key HighlightsMotixafortide effectively mobilized sufficient hematopoietic stem cells (HSCs) in patients with sickle cell disease enabling accelerated access to gene therapies90% (9 of 10) of patients ...
PharmiWeb

Shinoda Dental Named Official Distributor of VHF Milling Machines, Strengthening Its Position in Digital Dentistry

Authorized distribution partnership brings VHF's industry-leading milling technology to Shinoda Dental's global customers. SINGAPORE, SG / ACCESS Newswire / December 6, 2025 / Shinoda Dental is a top ...
PharmiWeb

Actio Biosciences Announces Preclinical Data Highlighting Ability of ABS-1230 to Potently and Selectively Inhibit KCNT1 and Significantly Reduce Seizure Activity

Data to be Presented During an Oral Platform Presentation at the American Epilepsy Society Annual MeetingSAN DIEGO--(BUSINESS ...
PharmiWeb

GraphiteRx and Mark Cuban Cost Plus Drugs Deepen Partnership to Advance Availability of Lower-Cost Medications

Powering the Cost Plus Marketplace for Businesses Through Transparency, Innovation and Trust Mark Cuban and David Zilberman ...
PharmiWeb

Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)

In the MZL cohort of TRANSCEND FL, Breyanzi delivered deep and durable responses in 95.5% of patients while demonstrating a ...
PharmiWeb

Alzheimer’s Drugs Market Projections 2025-2030: Key Trends, Opportunities, and Growth Factors in New Report

The Alzheimer’s drugs market is projected to grow at a compound annual growth rate (CAGR) of approximately 20% during the ...